<p>药明康德（NASDAQ:PAYX - 获取免费报告）于周三发布了其财报。这家商业服务提供商报告本季度每股收益（EPS）为 1.71 美元，超出市场共识预期的 1.68 美元，超出幅度为 0.03 美元。药明康德的股本回报率为 46.38%，净利润率为 26.45%。该公司本季度的收入为 18.1 亿美元，而分析师预期为 17.8 亿美元。在去年同期，该公司每股收益为 1.49 美元。药明康德本季度的收入同比增长 19.9%。</p>
<h2>药明康德价格表现</h2>
<ul>
<li>后期牛市是科技股的买入机会</li>
</ul>
<p>药明康德的股票周三开盘价为 90.61 美元。该公司的 50 日简单移动平均线为 97.72 美元，200 日简单移动平均线为 111.51 美元。药明康德的 12 个月低点为 86.89 美元，12 个月高点为 161.24 美元。该公司的市值为 325.3 亿美元，市盈率为 20.55，贝塔值为 0.91。该公司的速动比率为 1.27，流动比率为 1.27，债务与股本比率为 1.17。</p>
<h2>药明康德分红公告</h2>
<p>该公司最近宣布了季度分红，已于 2 月 27 日（星期五）支付。1 月 28 日（星期三）的股东记录获得每股 1.08 美元的分红。该分红的除息日为 1 月 28 日（星期三）。这代表着年化分红为 4.32 美元，收益率为 4.8%。药明康德目前的分红支付比率为 97.96%。</p>
<h2>药明康德的机构交易</h2>
<ul>
<li>3 只大盘股宣布大规模回购计划，股价下跌超过 20%</li>
</ul>
<p>一些机构投资者最近调整了对 PAYX 的持股。Bison Wealth LLC 在第四季度将其在药明康德的持股增加了 3.0%。Bison Wealth LLC 现在拥有 4,035 股该商业服务提供商的股票，价值 566,000 美元，此前在该期间内又购买了 117 股。Brighton Jones LLC 在第四季度将其在药明康德的股份增加了 26.3%。Brighton Jones LLC 现在拥有 5,710 股该商业服务提供商的股票，价值 801,000 美元，此前在该期间内又购买了 1,190 股。Stokes Family Office LLC 在第四季度将其在药明康德的持股增加了 26.1%。Stokes Family Office LLC 现在拥有 2,123 股该商业服务提供商的股票，价值 238,000 美元，此前在上个季度又收购了 439 股。Abel Hall LLC 在第四季度购买了药明康德的新头寸，价值约 232,000 美元。最后，Quarry LP 在第四季度将其在药明康德的持股增加了 1,541.7%。Quarry LP 现在拥有 1,970 股该商业服务提供商的股票，价值 221,000 美元，此前在该期间内又收购了 1,850 股。83.47% 的股票目前由对冲基金和其他机构投资者持有。</p>
<p>药明康德宣布其董事会已于 1 月 16 日（星期五）授权一项股票回购计划，允许公司回购 10 亿美元的股票。该回购授权允许该商业服务提供商通过公开市场购买最多 2.5% 的股份。股票回购计划通常表明公司的领导层认为其股票被低估。</p>
<h2>分析师设定新的价格目标</h2>
<ul>
<li>买入机会：药明康德在抛售后发出反弹信号</li>
</ul>
<p>一些股票研究分析师最近对 PAYX 股票发表了看法。Stifel Nicolaus 将药明康德的目标价从 137.00 美元下调至 126.00 美元，并在 12 月 17 日（星期三）的报告中对该公司给予 “持有” 评级。Wolfe Research 将药明康德的目标价从 130.00 美元下调至 115.00 美元，并在 12 月 10 日（星期三）的报告中对该股票给予 “表现不佳” 评级。Cantor Fitzgerald 在 1 月 27 日（星期二）的研究报告中将药明康德的评级上调至 “强烈卖出”。Jefferies Financial Group 在 12 月 19 日（星期五）的研究报告中设定了药明康德的目标价为 110.00 美元。最后，TD Cowen 在 12 月 1 日（星期一）的研究报告中重申了对药明康德的 “持有” 评级。一位研究分析师对该股票给予了买入评级，十四位分析师给予了持有评级，四位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “减持”，共识目标价为 121.38 美元。</p>
<p><strong>获取我们最新的药明康德股票分析</strong></p>
<h2>药明康德公司简介</h2>
<p>（获取免费报告）</p>
<p>药明康德公司成立于 1971 年，由 B. Thomas &#34;Tom&#34; Golisano 创立，总部位于纽约州罗切斯特，是一家为中小型企业提供薪资、人力资源和福利外包解决方案的公司。公司的核心服务包括薪资处理和税务申报、员工福利管理、退休服务和工伤赔偿管理，旨在简化后台操作并帮助客户遵守监管和税务要求。</p>
<p>药明康德提供一个集成的技术平台，品牌为 Paychex Flex，提供基于云的薪资、HR、考勤和报告工具。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过药明康德</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEFZWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEFZWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在药明康德吗？</h2>
<p>在考虑药明康德之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Paychex 并不在名单上。</p>
<p>虽然 Paychex 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

沛齐

<p>Paychex（纳斯达克代码：PAYX）报告的季度每股收益为 1.71 美元，超出预期 0.03 美元。该公司实现收入 18.1 亿美元，超过 1.78 亿美元的预期，同比增长 19.9%。Paychex 还宣布每股季度分红为 1.08 美元，收益率为 4.8%。该公司已授权进行 10 亿美元的股票回购计划。分析师对该股票的评级不一，包含一项买入、十四项持有和四项卖出</p>

<p>Paychex (NASDAQ:PAYX - Get Free Report) issued its earnings results on Wednesday. The business services provider reported $1.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.68 by $0.03, Briefing.com reports. Paychex had a return on equity of 46.38% and a net margin of 26.45%.The business had revenue of $1.81 billion during the quarter, compared to analyst estimates of $1.78 billion. During the same quarter in the prior year, the firm earned $1.49 earnings per share. Paychex's revenue for the quarter was up 19.9% on a year-over-year basis.</p>
<div class="lb-trans"><p>药明康德（NASDAQ:PAYX - 获取免费报告）于周三发布了其财报。这家商业服务提供商报告本季度每股收益（EPS）为 1.71 美元，超出市场共识预期的 1.68 美元，超出幅度为 0.03 美元。药明康德的股本回报率为 46.38%，净利润率为 26.45%。该公司本季度的收入为 18.1 亿美元，而分析师预期为 17.8 亿美元。在去年同期，该公司每股收益为 1.49 美元。药明康德本季度的收入同比增长 19.9%。</p>
</div><h2>Paychex Price Performance</h2>
<div class="lb-trans"><h2>药明康德价格表现</h2>
</div><ul>
<li>The Late-Stage Bull Market Is a Buying Opportunity for Tech</li>
</ul>
<div class="lb-trans"><ul>
<li>后期牛市是科技股的买入机会</li>
</ul>
</div><p>Shares of Paychex stock opened at $90.61 on Wednesday. The company's fifty day simple moving average is $97.72 and its two-hundred day simple moving average is $111.51. Paychex has a 12-month low of $86.89 and a 12-month high of $161.24. The firm has a market cap of $32.53 billion, a PE ratio of 20.55 and a beta of 0.91. The company has a quick ratio of 1.27, a current ratio of 1.27 and a debt-to-equity ratio of 1.17.</p>
<div class="lb-trans"><p>药明康德的股票周三开盘价为 90.61 美元。该公司的 50 日简单移动平均线为 97.72 美元，200 日简单移动平均线为 111.51 美元。药明康德的 12 个月低点为 86.89 美元，12 个月高点为 161.24 美元。该公司的市值为 325.3 亿美元，市盈率为 20.55，贝塔值为 0.91。该公司的速动比率为 1.27，流动比率为 1.27，债务与股本比率为 1.17。</p>
</div><h2>Paychex Dividend Announcement</h2>
<div class="lb-trans"><h2>药明康德分红公告</h2>
</div><p>The company also recently declared a quarterly dividend, which was paid on Friday, February 27th. Shareholders of record on Wednesday, January 28th were given a dividend of $1.08 per share. The ex-dividend date of this dividend was Wednesday, January 28th. This represents a $4.32 annualized dividend and a yield of 4.8%. Paychex's dividend payout ratio is presently 97.96%.</p>
<div class="lb-trans"><p>该公司最近宣布了季度分红，已于 2 月 27 日（星期五）支付。1 月 28 日（星期三）的股东记录获得每股 1.08 美元的分红。该分红的除息日为 1 月 28 日（星期三）。这代表着年化分红为 4.32 美元，收益率为 4.8%。药明康德目前的分红支付比率为 97.96%。</p>
</div><h2>Institutional Trading of Paychex</h2>
<div class="lb-trans"><h2>药明康德的机构交易</h2>
</div><ul>
<li>3 Large Cap Stocks Announce Big Buyback Boosts Amid +20% Falls</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只大盘股宣布大规模回购计划，股价下跌超过 20%</li>
</ul>
</div><p>A number of institutional investors have recently modified their holdings of PAYX. Bison Wealth LLC lifted its holdings in Paychex by 3.0% in the 4th quarter. Bison Wealth LLC now owns 4,035 shares of the business services provider's stock worth $566,000 after buying an additional 117 shares during the period. Brighton Jones LLC increased its stake in shares of Paychex by 26.3% during the fourth quarter. Brighton Jones LLC now owns 5,710 shares of the business services provider's stock valued at $801,000 after buying an additional 1,190 shares during the period. Stokes Family Office LLC raised its holdings in shares of Paychex by 26.1% during the fourth quarter. Stokes Family Office LLC now owns 2,123 shares of the business services provider's stock valued at $238,000 after acquiring an additional 439 shares in the last quarter. Abel Hall LLC bought a new position in shares of Paychex during the fourth quarter valued at approximately $232,000. Finally, Quarry LP lifted its stake in Paychex by 1,541.7% in the fourth quarter. Quarry LP now owns 1,970 shares of the business services provider's stock worth $221,000 after acquiring an additional 1,850 shares during the period. 83.47% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一些机构投资者最近调整了对 PAYX 的持股。Bison Wealth LLC 在第四季度将其在药明康德的持股增加了 3.0%。Bison Wealth LLC 现在拥有 4,035 股该商业服务提供商的股票，价值 566,000 美元，此前在该期间内又购买了 117 股。Brighton Jones LLC 在第四季度将其在药明康德的股份增加了 26.3%。Brighton Jones LLC 现在拥有 5,710 股该商业服务提供商的股票，价值 801,000 美元，此前在该期间内又购买了 1,190 股。Stokes Family Office LLC 在第四季度将其在药明康德的持股增加了 26.1%。Stokes Family Office LLC 现在拥有 2,123 股该商业服务提供商的股票，价值 238,000 美元，此前在上个季度又收购了 439 股。Abel Hall LLC 在第四季度购买了药明康德的新头寸，价值约 232,000 美元。最后，Quarry LP 在第四季度将其在药明康德的持股增加了 1,541.7%。Quarry LP 现在拥有 1,970 股该商业服务提供商的股票，价值 221,000 美元，此前在该期间内又收购了 1,850 股。83.47% 的股票目前由对冲基金和其他机构投资者持有。</p>
</div><p>Paychex announced that its Board of Directors has authorized a stock buyback plan on Friday, January 16th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the business services provider to buy up to 2.5% of its shares through open market purchases. Shares buyback plans are generally a sign that the company's leadership believes its stock is undervalued.</p>
<div class="lb-trans"><p>药明康德宣布其董事会已于 1 月 16 日（星期五）授权一项股票回购计划，允许公司回购 10 亿美元的股票。该回购授权允许该商业服务提供商通过公开市场购买最多 2.5% 的股份。股票回购计划通常表明公司的领导层认为其股票被低估。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><ul>
<li>Buy The Dip Opportunity: Paychex Signals Rebound After Sell-Off</li>
</ul>
<div class="lb-trans"><ul>
<li>买入机会：药明康德在抛售后发出反弹信号</li>
</ul>
</div><p>A number of equities research analysts have recently weighed in on PAYX shares. Stifel Nicolaus lowered their price objective on shares of Paychex from $137.00 to $126.00 and set a &#34;hold&#34; rating for the company in a report on Wednesday, December 17th. Wolfe Research reduced their target price on shares of Paychex from $130.00 to $115.00 and set an &#34;underperform&#34; rating on the stock in a report on Wednesday, December 10th. Cantor Fitzgerald upgraded shares of Paychex to a &#34;strong sell&#34; rating in a research report on Tuesday, January 27th. Jefferies Financial Group set a $110.00 price target on shares of Paychex in a research report on Friday, December 19th. Finally, TD Cowen reaffirmed a &#34;hold&#34; rating on shares of Paychex in a research note on Monday, December 1st. One research analyst has rated the stock with a Buy rating, fourteen have assigned a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of &#34;Reduce&#34; and a consensus target price of $121.38.</p>
<div class="lb-trans"><p>一些股票研究分析师最近对 PAYX 股票发表了看法。Stifel Nicolaus 将药明康德的目标价从 137.00 美元下调至 126.00 美元，并在 12 月 17 日（星期三）的报告中对该公司给予 “持有” 评级。Wolfe Research 将药明康德的目标价从 130.00 美元下调至 115.00 美元，并在 12 月 10 日（星期三）的报告中对该股票给予 “表现不佳” 评级。Cantor Fitzgerald 在 1 月 27 日（星期二）的研究报告中将药明康德的评级上调至 “强烈卖出”。Jefferies Financial Group 在 12 月 19 日（星期五）的研究报告中设定了药明康德的目标价为 110.00 美元。最后，TD Cowen 在 12 月 1 日（星期一）的研究报告中重申了对药明康德的 “持有” 评级。一位研究分析师对该股票给予了买入评级，十四位分析师给予了持有评级，四位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “减持”，共识目标价为 121.38 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on PAYX</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的药明康德股票分析</strong></p>
</div><h2>Paychex Company Profile</h2>
<div class="lb-trans"><h2>药明康德公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Paychex, Inc, founded in 1971 by B. Thomas &#34;Tom&#34; Golisano and headquartered in Rochester, New York, is a provider of payroll, human resources, and benefits outsourcing solutions for small- and medium-sized businesses. The company's core services include payroll processing and tax filing, employee benefits administration, retirement services, and workers' compensation administration, designed to simplify back-office operations and help clients comply with regulatory and tax requirements.</p>
<div class="lb-trans"><p>药明康德公司成立于 1971 年，由 B. Thomas &#34;Tom&#34; Golisano 创立，总部位于纽约州罗切斯特，是一家为中小型企业提供薪资、人力资源和福利外包解决方案的公司。公司的核心服务包括薪资处理和税务申报、员工福利管理、退休服务和工伤赔偿管理，旨在简化后台操作并帮助客户遵守监管和税务要求。</p>
</div><p>Paychex offers an integrated technology platform, marketed under the Paychex Flex brand, which delivers cloud-based payroll, HR, time and attendance, and reporting tools.</p>
<div class="lb-trans"><p>药明康德提供一个集成的技术平台，品牌为 Paychex Flex，提供基于云的薪资、HR、考勤和报告工具。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Paychex</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过药明康德</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEFZWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=PAYX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Paychex Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在药明康德吗？</h2>
</div><p>Before you consider Paychex, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑药明康德之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Paychex wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Paychex 并不在名单上。</p>
</div><p>While Paychex currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Paychex 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

沛齐（纳斯达克代码：PAYX）公布了财报结果，每股收益比预期高出 0.03 美元